日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

降低MDS患者参与临床试验的门槛:icMDS立场声明

Borate, Uma; Pugh, Kelly; Waller, Allyson; Welkie, Rina Li; Huang, Ying; Bewersdorf, Jan Philipp; Stahl, Maximilian; DeZern, Amy E; Platzbecker, Uwe; Sekeres, Mikkael A; Wei, Andrew H; Buckstein, Rena J; Roboz, Gail J; Savona, Michael R; Loghavi, Sanam; Hasserjian, Robert P; Fenaux, Pierre; Sallman, David A; Hourigan, Christopher S; Della Porta, Matteo Giovanni; Nimer, Stephen; Little, Richard F; Santini, Valeria; Efficace, Fabio; Taylor, Justin; Garcia-Manero, Guillermo; Odenike, Olatoyosi; Kim, Tae Kon; Halene, Stephanie; Komrokji, Rami S; Griffiths, Elizabeth A; Greenberg, Peter L; Xu, Mina L; Xie, Zhuoer; Bejar, Rafael; Sanz, Guillermo F; Patnaik, Mrinal M; Figueroa, Maria; Carraway, Hetty E; Abdel-Wahab, Omar; Starczynowski, Daniel; Padron, Eric; Boultwood, Jacqueline; Gore, Steven; Daver, Naval G; Churpek, Jane E; Majeti, Ravindra; Bennett, John M; List, Alan F; Brunner, Andrew M; Zeidan, Amer M

Genome-wide in vivo CRISPR screens identify GATOR1 complex as a tumor suppressor in Myc-driven lymphoma.

全基因组体内 CRISPR 筛选发现 GATOR1 复合物是 Myc 驱动淋巴瘤中的肿瘤抑制因子

Potts Margaret A, Mizutani Shinsuke, Deng Yexuan, Vaidyanathan Srimayee, Ting Keziah E, Giner Göknur, Sridhar Shruti, Shenoy Girija, Liao Yang, Diepstraten Sarah T, Kueh Andrew J, Pal Martin, Healey Geraldine, Tai Lin, Wang Zilu, König Christina, Kaloni Deeksha, Whelan Lauren, Milevskiy Michael J G, Coughlan Hannah D, Pomilio Giovanna, Wei Andrew H, Visvader Jane E, Papenfuss Anthony T, Wilcox Stephen, Jeyasekharan Anand D, Shi Wei, Lelliott Emily J, Kelly Gemma L, Brown Kristin K, Strasser Andreas, Herold Marco J

Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins.

重新评估在透化血癌细胞上测试维奈托克或其他 BH3 模拟剂的试验,这些药物选择性地靶向促生存 BCL2 蛋白

Gong Jia-Nan, Djajawi Tirta M, Moujalled Donia M, Pomilio Giovanna, Khong Tiffany, Zhang Li-Ping, Fedele Pasquale L, Low Michael S, Anderson Mary Ann, Riffkin Christopher D, White Christine A, Lan Ping, Lessene Guillaume, Herold Marco J, Strasser Andreas, Spencer Andrew, Grigoriadis George, Wei Andrew H, van Delft Mark F, Roberts Andrew W, Huang David C S

Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia

维奈托克和阿扎胞苷用于未经治疗的治疗相关性急性髓系白血病、既往骨髓增生异常综合征或慢性粒单核细胞白血病患者

Pullarkat, Vinod; Pratz, Keith W; Döhner, Hartmut; Recher, Christian; Thirman, Michael J; DiNardo, Courtney D; Fenaux, Pierre; Schuh, Andre C; Wei, Andrew H; Pigneux, Arnaud; Jang, Jun-Ho; Juliusson, Gunnar; Miyazaki, Yasushi; Selleslag, Dominik; Arellano, Martha L; Liu, Chenglong; Ridgeway, Jean A; Potluri, Jalaja; Schuler, Jovita; Konopleva, Marina

Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide

优化急性髓系白血病低强度三联疗法:实用指南

Jen, Wei-Ying; Lachowiez, Curtis A; Marvin-Peek, Jennifer; Altman, Jessica K; Yilmaz, Musa; Garcia, Jacqueline S; Abaza, Yasmin; Short, Nicholas J; Zeidner, Joshua F; Daver, Naval G; Wei, Andrew H; Issa, Ghayas C; DiNardo, Courtney D

Triplet regimens for all: genomically agnostic approaches to improve on HMA + VEN in AML?

适用于所有患者的三联疗法:基因组无关的治疗方法能否改善急性髓系白血病(AML)中 HMA + VEN 的疗效?

Nicol, William; Wei, Andrew H

Research priorities to address supportive care needs in acute myeloid leukaemia (AML)-results from a Delphi survey

针对急性髓系白血病 (AML) 支持性护理需求的研究重点——德尔菲调查结果

Parker, Catriona; Weinkove, Robert; Wei, Andrew H; McQuilten, Zoe K

Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3

吉瑞替尼用于FLT3内部串联重复突变型急性髓系白血病移植后维持治疗

Levis, Mark J; Hamadani, Mehdi; Logan, Brent; Jones, Richard J; Singh, Anurag K; Litzow, Mark; Wingard, John R; Papadopoulos, Esperanza B; Perl, Alexander E; Soiffer, Robert J; Ustun, Celalettin; Ueda Oshima, Masumi; Uy, Geoffrey L; Waller, Edmund K; Vasu, Sumithra; Solh, Melhem; Mishra, Asmita; Muffly, Lori; Kim, Hee-Je; Mikesch, Jan-Henrik; Najima, Yuho; Onozawa, Masahiro; Thomson, Kirsty; Nagler, Arnon; Wei, Andrew H; Marcucci, Guido; Geller, Nancy L; Hasabou, Nahla; Delgado, David; Rosales, Matt; Hill, Jason; Gill, Stanley C; Nuthethi, Rishita; King, Denise; Wittsack, Heather; Mendizabal, Adam; Devine, Steven M; Horowitz, Mary M; Chen, Yi-Bin

Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)

使用维奈托克和低剂量阿糖胞苷靶向治疗 AML 中的分子可测量残留病灶和低原始细胞复发:一项前瞻性 II 期研究 (VALDAC)

Tiong, Ing Soo; Hiwase, Devendra K; Abro, Emad; Bajel, Ashish; Palfreyman, Emma; Beligaswatte, Ashanka; Reynolds, John; Anstee, Natasha; Nguyen, Tamia; Loo, Sun; Chua, Chong Chyn; Ashby, Michael; Wiltshire, Kaitlyn M; Fleming, Shaun; Fong, Chun Y; Teh, Tse-Chieh; Blombery, Piers; Dillon, Richard; Ivey, Adam; Wei, Andrew H

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

维奈托克和阿扎胞苷治疗初治急性髓系白血病患者的遗传风险分层和预后

Döhner, Hartmut; Pratz, Keith W; DiNardo, Courtney D; Wei, Andrew H; Jonas, Brian A; Pullarkat, Vinod A; Thirman, Michael J; Récher, Christian; Schuh, Andre C; Babu, Sunil; Li, Xiaotong; Ku, Grace; Liu, Zihuan; Sun, Yan; Potluri, Jalaja; Dail, Monique; Chyla, Brenda; Pollyea, Daniel A